CHM chimeric therapeutics limited

Ann: Phase 1B CHM CORE-NK trial advances to newly diagnosed AML, page-17

  1. 8,328 Posts.
    lightbulb Created with Sketch. 3661
    It could open the door to other frontline combination therapies for CORE-NK beyond AML too.

    Positive prelim data from the CDH17 trial should be the catalyst for some serious SP accretion, don't you think?


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $20 5K

Buyers (Bids)

No. Vol. Price($)
27 21893606 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 18993063 28
View Market Depth
Last trade - 11.34am 17/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.